Abstract
Purpose Most research on genetic screening and precision oncology is based on participants of European ancestry, making it vital to evaluate the performance of these approaches in diverse populations. We analysed data from the 100,000 Genomes Project (100kGP) to assess ancestry-related differences in cancer variant prioritisation.
Patients and Methods To assess the representativeness of the 14,775 participants with cancer from the 100kGP, we compared recruitment ratios for self-reported ethnicities to those in England. For genetic ancestry groups we analysed differences in detection rates for potential pathogenic variants (PVs) in the germline and somatic mutations in genes with treatment implications and investigated possible causes of observed disparities.
Results Recruitment rates for Black and Asian ethnicities compared with White ethnicity in the 100kGP were consistent with rates in England, except for bladder and prostate (Black and Asian) and breast (Asian only) where Black and Asian ethnicities were recruited at higher rates than expected compared to White ethnicity.
Patients with non-European genetic ancestry were more likely to carry variants classified as potential pathogenic compared to European ancestry (p=0.006). PVs were identified in 4.6% of South Asian (adjusted model: odds ratio=1.88, 95%CI=1.21-2.93) and 5.3% of African ancestry patients (odds ratio=2.24, 95%CI=1.44-3.48) compared with 2.2% in European.
Fewer non-synonymous somatic mutations in actionable genes were identified in patients of non-European ancestry (p=0.004). WGS failed to identify treatment-relevant findings for 26% of patients of South Asian ancestry compared with 16% of European ancestry.
Conclusion The excess germline variants classified as PVs in patients with non-European ancestry may impede the diagnostic process. Our analysis demonstrates the need for better variant classification across diverse ancestries to ensure equitable implementation of genomics in cancer care.
Competing Interest Statement
T. Nguyen became affiliated with e-Therapeutics PLC after her contribution to this manuscript.
Funding Statement
This research was made possible through access to data in the National Genomic Research Library, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The National Genomic Research Library holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The National Genomic Research Library is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. KK was also supported by the European Union under the Horizon 2020 research and innovation programme (No 948561).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our analysis was limited to patients in the version 15 release of the National Genomic Research Library (NGRL)12, a database of WGS and linked health data from consenting National Health Service (NHS) patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclaimers: T. Nguyen became affiliated with e-Therapeutics PLC after her contribution to this manuscript.
Data Availability
The data supporting the findings of this study are available within the Genomics England Research Environment, a secure cloud workspace. Details on how to access data for this publication can be found at https://re-docs.genomicsengland.co.uk/pan_cancer_pub/. To access the genomic and clinical data within this Research Environment, researchers must first apply to become a member of either the Genomics England Research Network (previously known as the Genomics England Clinical Interpretation Partnership, GECIP) (www.genomicsengland.co.uk/research/academic) or a Discovery Forum industry partner (www.genomicsengland.co.uk/research/research-environment). The process for joining the Genomics England Research Network is described at www.genomicsengland.co.uk/research/academic/join-gecip. Data that have been made available to registered users include: alignments in BAM or CRAM format; annotated variant calls in VCF format; signature assignment; tumour mutational burden; sequencing quality metrics; summary of findings shared with the Genomic Lab Hubs; and secondary clinical data as described in this paper.
https://www.genomicsengland.co.uk/research/academic/join-gecip
